Clinical Trial Update: Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial assessed the efficacy of Gaviscon-Advance in reducing post-supper acid pockets and night-time acid reflux in obese participants with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease
• Obesity

Drugs mentioned

• Gaviscon-Advance (sodium alginate-based antacid (sodium alginate with antacid salts))

Snippet

Sponsor: Universiti Sains Malaysia | Conditions: Gastroesophageal Reflux Disease, Acid Reflux | Phase 2, Phase 3 | Status: COMPLETED